Free Trial
NASDAQ:DCTH

Delcath Systems Q2 2023 Earnings Report

Delcath Systems logo
$16.19 -0.22 (-1.34%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$16.18 -0.01 (-0.03%)
As of 05/28/2025 06:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Delcath Systems EPS Results

Actual EPS
-$0.58
Consensus EPS
-$0.67
Beat/Miss
Beat by +$0.09
One Year Ago EPS
N/A

Delcath Systems Revenue Results

Actual Revenue
$0.50 million
Expected Revenue
$0.73 million
Beat/Miss
Missed by -$230.00 thousand
YoY Revenue Growth
N/A

Delcath Systems Announcement Details

Quarter
Q2 2023
Time
N/A
Conference Call Date
Wednesday, August 9, 2023
Conference Call Time
8:00AM ET

Upcoming Earnings

Delcath Systems' Q2 2025 earnings is scheduled for Monday, August 4, 2025, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Delcath Systems Earnings Headlines

HC Wainwright Weighs in on Delcath Systems Q1 Earnings
Delcath Systems (NASDAQ:DCTH) Price Target Raised to $29.00
Trump’s treachery
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
Delcath Systems Issues Full Year 2025 Guidance
See More Delcath Systems Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Delcath Systems? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Delcath Systems and other key companies, straight to your email.

About Delcath Systems

Delcath Systems (NASDAQ:DCTH), an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

View Delcath Systems Profile

More Earnings Resources from MarketBeat